David B. Seaburg Insider Information
David Seaburg currently serves as Chair of the Board’s Strategic Review Committee and was previously a director from August 2018 to August 2019. Mr. Seaburg served as PolarityTE’s Chief Executive Officer from April 2020 through August 2021, President of Corporate Development from January 2019 to August 2019. During Mr. Seaburg’s tenure in management, the Company completed several significant restructuring initiatives, primarily focused on reducing costs, enhancing sales of SkinTE® when it was previously marketed as a 361 HCT/P, and preparing PolarityTE for the changes that would be required from a regulatory perspective for SkinTE following the conclusion of FDA’s period of enforcement discretion for 361 HCT/Ps in May 2021. Prior to PolarityTE, Mr. Seaburg spent roughly 25 years of his career at Cowen, Inc., a leading healthcare franchise in equities research, sales and investment banking. He was Managing Director, Head of Sales Trading and a member of the Cowen’s Equity Operating Committee, where he cultivated and led teams operating across multiple disciplines and specialties, leveraging human capital to drive the organization’s success. Over the course of his tenure, he interacted with thousands of healthcare investors and corporate management teams. Mr. Seaburg was also a CNBC Fast Money Contributor, where he provided regular on-air market commentary for the network.
What is David B. Seaburg's net worth?
The estimated net worth of David B. Seaburg is at least $2.63 million as of July 19th, 2021. Mr. Seaburg owns 1,120,023 shares of PolarityTE stock worth more than $2,632,054 as of May 22nd. This net worth estimate does not reflect any other assets that Mr. Seaburg may own. Learn More about David B. Seaburg's net worth.
How do I contact David B. Seaburg?
Has David B. Seaburg been buying or selling shares of PolarityTE?
Who are PolarityTE's active insiders?
Are insiders buying or selling shares of PolarityTE?
In the last twelve months, insiders at the sold shares 4 times. They sold a total of 80,980 shares worth more than $54,486.29. The most recent insider tranaction occured on October, 19th when Director David B Seaburg sold 31,037 shares worth more than $17,070.35. Insiders at PolarityTE own 5.4 % of the company.
Learn More about insider trades at PolarityTE. Information on this page was last updated on 10/19/2021.
David B. Seaburg Insider Trading History at PolarityTE
| Transaction Date | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/19/2021 | Sell | 31,037 | $0.55 | $17,070.35 | |  |
| 7/19/2021 | Sell | 31,032 | $0.71 | $22,032.72 | 1,120,023 | |
| 4/19/2021 | Sell | 31,031 | $0.86 | $26,686.66 | 1,129,813 | |
| 1/19/2021 | Sell | 31,037 | $1.10 | $34,140.70 | 880,240 | |
| 12/30/2020 | Sell | 8,515 | $0.67 | $5,705.05 | 911,277 | |
| 10/19/2020 | Sell | 31,032 | $1.02 | $31,652.64 | 919,792 | |
| 9/30/2020 | Sell | 8,514 | $1.03 | $8,769.42 | 950,824 | |
| 7/1/2020 | Sell | 8,514 | $1.28 | $10,897.92 | 1,002,451 | |
| 3/31/2020 | Sell | 21,287 | $1.04 | $22,138.48 | 345,965 | |
| 2/7/2020 | Sell | 16,333 | $3.02 | $49,325.66 | 372,701 | |
PolarityTE Company Overview
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
Read More
Volume
265,605 shs
Average Volume
316,428 shs
Market Capitalization
$9.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.13
